Cargando…

Integration of a Physiologically Based Pharmacokinetic and Pharmacodynamic Model for Tegoprazan and Its Metabolite: Application for Predicting Food Effect and Intragastric pH Alterations

A physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model for tegoprazan and its major metabolite M1 was developed to predict PK and PD profiles under various scenarios. The PBPK model for tegoprazan and M1 was developed and predicted using the SimCYP(®) simulator and verified using cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jeong, Hyeon-Cheol, Kim, Min-Gul, Wei, Zhuodu, Lee, Kyeong-Ryoon, Lee, Jaehyeok, Song, Im-Sook, Shin, Kwang-Hee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9230797/ https://www.ncbi.nlm.nih.gov/pubmed/35745870 http://dx.doi.org/10.3390/pharmaceutics14061298

Ejemplares similares

Prediction of the Drug–Drug Interaction Potential between Tegoprazan and Amoxicillin/Clarithromycin Using the Physiologically Based Pharmacokinetic and Pharmacodynamic Model
por: Wei, Zhuodu, et al.
Publicado: (2023)

Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers
por: Yoon, Deok Y., et al.
Publicado: (2021)

A population PK–PD model of YH4808, a novel P‐CAB, and intragastric pH that incorporated negative feedback by increased intragastric pH onto the systemic exposure to YH4808
por: Chung, Tae Kyu, et al.
Publicado: (2022)

Prediction of Drug–Drug Interaction Potential of Tegoprazan Using Physiologically Based Pharmacokinetic Modeling and Simulation
por: Yoon, Deok Yong, et al.
Publicado: (2021)

Comparison of pharmacokinetic characteristics of two Tegoprazan (CJ-12420) formulations in healthy male subjects
por: Hwang, Jun Gi, et al.
Publicado: (2019)

Co-Administration of Vonoprazan, Not Tegoprazan, Affects the Pharmacokinetics of Atorvastatin in Healthy Male Subjects
por: Hwang, Sejung, et al.
Publicado: (2021)

Evaluation of pharmacokinetic drug-drug interaction between tegoprazan and clarithromycin in healthy subjects
por: Oh, Minkyung, et al.
Publicado: (2023)

Development of a Physiologically Based Pharmacokinetic Model for Tegoprazan: Application for the Prediction of Drug–Drug Interactions with CYP3A4 Perpetrators
por: Ngo, Lien Thi, et al.
Publicado: (2023)

Role of Tegoprazan in Helicobacter pylori Eradication Therapy
por: Lee, Jin
Publicado: (2022)

Comparison of Pharmacodynamics between Tegoprazan and Dexlansoprazole Regarding Nocturnal Acid Breakthrough: A Randomized Crossover Study
por: Han, Sungpil, et al.
Publicado: (2023)

Physiologically-based pharmacokinetic model for clozapine in Korean patients with schizophrenia
por: Lee, Joomi, et al.
Publicado: (2021)

Evaluation of CYP2C19-Mediated Pharmacokinetic Drug Interaction of Tegoprazan, Compared with Vonoprazan or Esomeprazole
por: Yang, Eunsol, et al.
Publicado: (2023)

Mechanisms of Intragastric pH Sensing
por: Goo, Tyralee, et al.
Publicado: (2010)

Development of Physiologically Based Pharmacokinetic Model for Orally Administered Fexuprazan in Humans
por: Jeong, Yoo-Seong, et al.
Publicado: (2021)

Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites
por: Darwish, Mona, et al.
Publicado: (2015)

Randomised clinical trial: comparison of tegoprazan and placebo in non‐erosive reflux disease
por: Kim, Seung Han, et al.
Publicado: (2021)

Pharmacokinetic Characterization of Supinoxin and Its Physiologically Based Pharmacokinetic Modeling in Rats
por: Song, Yoo-Kyung, et al.
Publicado: (2021)

Comparative Efficacy of 14-Day Tegoprazan-Based Triple vs. 10-Day Tegoprazan-Based Concomitant Therapy for Helicobacter pylori Eradication
por: Park, Chan Hyuk, et al.
Publicado: (2022)

Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine
por: Kiss, Béla, et al.
Publicado: (2019)

Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis
por: Cho, Yu Kyung, et al.
Publicado: (2022)

Night‐time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole
por: Yang, Eunsol, et al.
Publicado: (2022)

Intragastric pH of foals admitted to the intensive care unit
por: Wise, Jessica C., et al.
Publicado: (2020)

Comparison of hepatotoxicity of tegoprazan, a novel potassium-competitive acid blocker, with proton pump inhibitors using real-world data: A nationwide cohort study
por: Kim, Min-Gul, et al.
Publicado: (2023)

Efficacy of Tegoprazan in Patients with Laryngopharyngeal Reflux Disease: A Preliminary Feasibility Study
por: Jeon, Hye Kyung, et al.
Publicado: (2023)

Efficacy of Tegoprazan for Improving the Susceptibility of Antimicrobial Agents against Antibiotic-Resistant Helicobacter pylori
por: Lee, Jung Won, et al.
Publicado: (2021)

Pharmacokinetics of Shikimic Acid Following Intragastric and Intravenous Administrations in Rats
por: Noh, Keumhan, et al.
Publicado: (2020)

Population Pharmacokinetics of Hydroxychloroquine and 3 Metabolites in COVID-19 Patients and Pharmacokinetic/Pharmacodynamic Application
por: Alvarez, Jean Claude, et al.
Publicado: (2022)

Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody‐Drug Conjugates
por: Li, Chunze, et al.
Publicado: (2020)

Pharmacodynamic evaluation of intragastric pH and implications for famotidine dosing in the prophylaxis of non-steroidal anti-inflammatory drug induced gastropathy—a proof of concept analysis
por: Kent, Jeffery D., et al.
Publicado: (2014)

Pharmacokinetic‐pharmacodynamic integration of enrofloxacin and its metabolite ciprofloxacin in buffalo calves
por: Daundkar, Prashant S., et al.
Publicado: (2015)

Metabolites profiling and pharmacokinetics of troxipide and its pharmacodynamics in rats with gastric ulcer
por: Guo, Hongbin, et al.
Publicado: (2020)

Population Pharmacokinetics and Pharmacodynamics of Isoniazid and its Metabolite Acetylisoniazid in Chinese Population
por: Chen, Bing, et al.
Publicado: (2022)

Effect of Lactic Acid Bacteria on the Pharmacokinetics and Metabolism of Ginsenosides in Mice
por: Jeon, Ji-Hyeon, et al.
Publicado: (2021)

Clinical Pharmacokinetics and Pharmacodynamics of Dalcetrapib
por: Black, Donald M., et al.
Publicado: (2018)

Physiologically‐based pharmacokinetic pharmacodynamic parent‐metabolite model of edoxaban to predict drug–drug‐disease interactions: M4 contribution
por: Xu, Ruijuan, et al.
Publicado: (2023)

Optimizing the intragastric pH as a supportive therapy in upper GI bleeding.
por: Brunner, G., et al.
Publicado: (1996)

Evaluation of the Effect of Orally Administered Acid Suppressants On Intragastric pH in Cats
por: Parkinson, S., et al.
Publicado: (2014)

Development of Physiologically Based Pharmacokinetic/Pharmacodynamic Model for Indomethacin Disposition in Pregnancy
por: Alqahtani, Saeed, et al.
Publicado: (2015)

Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem in CKD and hemodialysis individuals
por: Deng, Guoliang, et al.
Publicado: (2023)

Physiologically-Based Pharmacokinetic Modelling to Predict the Pharmacokinetics and Pharmacodynamics of Linezolid in Adults and Children with Tuberculous Meningitis
por: Litjens, Carlijn H. C., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cqadf7a93inh4uq6r2fn12v0fs